Meanwhile, Relyvrio has already been conditionally approved in Canada under the Albrioza brand name, although it has not yet launched there, as Amylyx remains in pricing negotiations.

Amylyx confirmed today that it will withdraw its amyotrophic lateral sclerosis (ALS) therapy Relyvrio/Albrioza from the market in the US and Canada, shortly after the drug failed a clinical trial.

The trial marks a continuation of Amylyx's efforts in the disease following last year’s market withdrawal of Relyvrio (sodium phenylbutyrate and taurursodiol). The drug failed to beat placebo at ...

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat.com ...

Amylyx expects LUMINA to begin in early 2025. The company in March said its ALS drug Relyvrio had failed a late-stage clinical trial, and the stock has sunk more than 78% over the past year.

Amylyx Pharmaceuticals expressed that any forward ... The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the ...

The US Food and Drug Administration (FDA) has lifted a clinical hold on Amylyx Pharmaceuticals’ Phase I trial of AMX0114 in amyotrophic lateral sclerosis (ALS). The lift allows Amylyx to open US ...

Amylyx Pharmaceuticals (NASDAQ:AMLX) has priced a public offering of ~17.14M shares of its common stock at $3.50 a share. In addition, Amylyx has granted the underwriter a 30-day option to ...